Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Times of Africa.
Press releases published on April 29, 2025
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire
·
April 29, 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
Nautilus Biotechnology Reports First Quarter 2025 Financial Results
GlobeNewswire
·
April 29, 2025
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. “In Q1, …
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
GlobeNewswire
·
April 29, 2025
WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
OneMedNet’s regulatory-grade imaging Real-World Data (iRWD) now available in HealthVerity Marketplace™
GlobeNewswire
·
April 29, 2025
MINNEAPOLIS, April 29, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD), the leading provider of regulatory-grade imaging Real-World Data (iRWD), today announced that its iRWD solution is now available in HealthVerity Marketplace™, enabling …
Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress
GlobeNewswire
·
April 29, 2025
CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six …
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald
GlobeNewswire
·
April 29, 2025
WARREN, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today reminds that CEO Dr. Ryan Saadi MD, MPH will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be …
Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting
GlobeNewswire
·
April 29, 2025
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical …
Inspire Medical Systems, Inc. to Present at the BofA Securities 2025 Health Care Conference
GlobeNewswire
·
April 29, 2025
MINNEAPOLIS, April 29, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive …
Apyx Medical Corporation Announces Two Peer-Reviewed Publications on the Use of Renuvion in Abdominal Body Contouring Procedures
GlobeNewswire
·
April 29, 2025
Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients …
Annovis Bio Appoints Hui Liu as Director of Biostatistics
GlobeNewswire
·
April 29, 2025
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) …
Incyclix Bio Granted U.S. FDA Fast Track Designation for INX-315 to Treat CCNE1-Amplified Platinum-Resistant/Refractory Ovarian Cancer
GlobeNewswire
·
April 29, 2025
RESEARCH TRIANGLE PARK, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today …
Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting
GlobeNewswire
·
April 29, 2025
CHARLESTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial …
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD
GlobeNewswire
·
April 29, 2025
Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company …
Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF)
GlobeNewswire
·
April 29, 2025
WATERTOWN, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences
GlobeNewswire
·
April 29, 2025
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new clinical …
Immutep Quarterly Activities Report Q3 FY25
GlobeNewswire
·
April 29, 2025
Media Release First patient safely dosed in TACTI-004 Phase III lung cancer trial, marking a significant milestone Pivotal TACTI-004 trial design presented at the European Lung Cancer Congress (ELCC) 2025 Patient enrolment completed for the EFTISARC-NEO …
Reviva to Participate in the Citizens Life Sciences Conference
GlobeNewswire
·
April 29, 2025
CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of …
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
GlobeNewswire
·
April 29, 2025
Study supported by the Michael J. Fox Foundation through a grant awarded to ZyVersa and leading inflammasome experts at University of Miami Miller School of Medicine who conducted the study. Parkinson’s Disease (PD) affects over 10 million people globally …
Aurora Spine Corporation Announces Fourth Quarter and Fiscal Year 2024 Financial Results
GlobeNewswire
·
April 29, 2025
-Company reports record revenue of $17.6 million for FY 2024, an increase of 21% – -Company to host conference call Today, Tuesday, April 29th at 11am ET/8am PT – NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES CARLSBAD, Calif …
Die Olon Group festigt ihre Führungsposition im Bereich Bioproduktion durch zwei strategische Ernennungen in Frankreich
GlobeNewswire
·
April 29, 2025
MAILAND, April 29, 2025 (GLOBE NEWSWIRE) -- Die Olon Group, ein weltweit führender CDMO-Anbieter im Pharmabereich, gibt die Ernennung von Jérôme Bédier zum CEO seiner französischen Unternehmen und von Andrea Conforto zum M…